Michael Rosenbloom, MD
Neurology · Seattle, WANPI 1255454393
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,328 of the $178,673 with a category attached, or 61.7%. Eisai Inc. accounts for 72.8% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $92,992, more than ten times the $5,203 reported in 2021. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $815.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$130K
- Lilly USA, LLC$24K
- Janssen Global Services, LLC$10K
- Biogen$5K
- Shimadzu Precision Instruments, Inc.$5K
- Eisai CO., LTD.$2K
- plus $2K from 3 others
Across 120 payments — averaging $13,909 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$618K
- UCB SA$511K
- Eli Lilly$414K
- Novo Nordisk AS$46K
- Novartis$45K
- Biogen$32K
- plus $3K from 1 others
What the payments were for
- Consulting fees$44,22625%
- Speaking & faculty fees$110,32862%
- Travel & lodging$15,3719%
- Food & beverage$3,7492%
- Entertainment$5,0003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 162 | $130,118 |
| Lilly USA, LLC | 33 | $24,485 |
| Janssen Global Services, LLC | 12 | $9,977 |
| Biogen | 3 | $5,085 |
| Shimadzu Precision Instruments, Inc. | 1 | $5,000 |
| Eisai CO., LTD. | 1 | $2,000 |
| Genentech, Inc. | 1 | $1,695 |
| Atricure, Inc. | 5 | $195 |
| Omniscient Neurotechnology America Ltd | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$178,673 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 57 | $10,164 |
| Donepezil Hcl | 240 | $2,811 |
| Memantine Hcl | 59 | $1,044 |
| Escitalopram Oxalate | 64 | $649 |
| Sertraline Hcl | 66 | $559 |
| Quetiapine Fumarate | 34 | $515 |
| Propranolol Hcl | 17 | $508 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $501 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $430 |
| Trazodone Hcl | 14 | $75 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
- Leo WangSeattle$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.